Literature DB >> 23165426

Safety of osteoanabolic therapy: a decade of experience.

Cristiana Cipriani1, Cristiana Capriani, Dinaz Irani, John P Bilezikian.   

Abstract

Mesh：

Substances：

Year:  2012        PMID： 23165426     DOI： 10.1002/jbmr.1800

Source DB:  PubMed          Journal:  J Bone Miner Res        ISSN： 0884-0431            Impact factor:   6.741


× No keyword cloud information.
  51 in total

Review 1.  Role of sclerostin in bone and cartilage and its potential as a therapeutic target in bone diseases.

Authors:  E Michael Lewiecki
Journal:  Ther Adv Musculoskelet Dis       Date:  2014-04       Impact factor: 5.346

Review 2.  Hypoparathyroidism.

Authors:  John P Bilezikian
Journal:  J Clin Endocrinol Metab       Date:  2020-06-01       Impact factor: 5.958

Review 3.  Osteoporosis Treatment: When to Discontinue and When to Re-start.

Authors:  Silvano Adami; Luca Idolazzi; Elena Fracassi; Davide Gatti; Maurizio Rossini
Journal:  Bone Res       Date:  2013-12-31       Impact factor: 13.567

Review 4.  Sclerostin and skeletal health.

Authors:  Maryam Sharifi; Lisa Ereifej; E Michael Lewiecki
Journal:  Rev Endocr Metab Disord       Date:  2015-06       Impact factor: 6.514

5.  Suppression of Sclerostin Alleviates Radiation-Induced Bone Loss by Protecting Bone-Forming Cells and Their Progenitors Through Distinct Mechanisms.

Authors:  Abhishek Chandra; Tiao Lin; Tiffany Young; Wei Tong; Xiaoyuan Ma; Wei-Ju Tseng; Ina Kramer; Michaela Kneissel; Michael A Levine; Yejia Zhang; Keith Cengel; X Sherry Liu; Ling Qin
Journal:  J Bone Miner Res       Date:  2016-10-20       Impact factor: 6.741

Review 6.  Osteoanabolic and dual action drugs.

Authors:  Gaia Tabacco; John P Bilezikian
Journal:  Br J Clin Pharmacol       Date:  2019-04-03       Impact factor: 4.335

Review 7.  Recombinant Human Parathyroid Hormone (1-84): A Review in Hypoparathyroidism.

Authors:  Esther S Kim; Gillian M Keating
Journal:  Drugs       Date:  2015-07       Impact factor: 9.546

8.  Parathyroid hormone therapy for hypoparathyroidism.

Authors:  Natalie E Cusano; Mishaela R Rubin; John P Bilezikian
Journal:  Best Pract Res Clin Endocrinol Metab       Date:  2014-09-10       Impact factor: 4.690

9.  Proteasome inhibitor bortezomib is a novel therapeutic agent for focal radiation-induced osteoporosis.

Authors:  Abhishek Chandra; Luqiang Wang; Tiffany Young; Leilei Zhong; Wei-Ju Tseng; Michael A Levine; Keith Cengel; X Sherry Liu; Yejia Zhang; Robert J Pignolo; Ling Qin
Journal:  FASEB J       Date:  2017-08-31       Impact factor: 5.191

10.  Loss of Nmp4 optimizes osteogenic metabolism and secretion to enhance bone quality.

Authors:  Yu Shao; Emily Wichern; Paul J Childress; Michele Adaway; Jagannath Misra; Angela Klunk; David B Burr; Ronald C Wek; Amber L Mosley; Yunlong Liu; Alexander G Robling; Nickolay Brustovetsky; James Hamilton; Kylie Jacobs; Deepak Vashishth; Keith R Stayrook; Matthew R Allen; Joseph M Wallace; Joseph P Bidwell
Journal:  Am J Physiol Endocrinol Metab       Date:  2019-01-15       Impact factor: 4.310
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.